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To the Editor:
Chronic HBV is a leading cause of hepatocellular carcinoma (HCC)
worldwide. Targeting viral antigens with immunotherapy seems
an attractive treatment option. Bertoletti and colleagues have
now taken a well-appreciated ﬁrst step towards clinical applica-
tion by treating an HBV-related HCC patient with autologous T
cells engineered to recognize HBV surface antigen (HBsAg) [1].
The patient presented with recurrent HCC after liver trans-
plantation. HBsAg was expressed by metastasized tumor cells
but not donor-derived liver hepatocytes. Upon immunotherapy
with HBsAg-speciﬁc T cells, a drop in blood HBsAg accompanied
by T cell activation and degranulation was observed, from which
the authors concluded tumor cells were recognized and attacked.
With this result they claim to ‘‘conﬁrm the feasibility of providing
autologous TCR-redirected therapy against HCC and advocate this
strategy as a novel therapeutic opportunity in hepatitis B-associ-
ated malignancies’’. Although we acknowledge HBsAg-speciﬁc T
cell activation occurred, we wonder whether sufﬁcient evidence
was provided to conclude that T cells really acted on tumor cells
and whether this therapeutic approach is feasible. Furthermore,
based on previous reports on (limited) HBV antigen-expression
by tumor cells and the very restricted eligible patient group, we
challenge the therapeutic opportunity presented.
A primary question is whether HBV antigens represent feasible
targets for immunotherapy against HCC. For a long lasting thera-
peutic effect, HBV antigens need to be; (1) stably expressed by
tumor cells and presented in major histocompatibility complex
(MHC)-I and; (2) absent/lowonnon-tumor tissue toprevent collat-
eral damage. We have serious doubts these conditions are met in
sufﬁcient patients to justify further development of HBV antigen-
targeted therapies for HCC, in the context of liver transplantation
or not.
Although the tumors of the patient described byQasimand col-
leagues were positive for HBsAg and MHC-HBsAg peptide com-
plexes, they did not test if the tumor evolved to an HBsAg
negative state once under immune attack. Importantly, a recent
study by Faria and colleagues showed that despite presence of
HBV DNA in most HCC recurrences, HBsAg (and other HBV anti-
gens) are only detected in a minority of recurrent tumors [2].
Although HBV DNA integrates into the host genome in 85–90% of
patients, integrations often lead to disruption of viral proteins
and expression of HBV-host fusion constructs [3,4]. Moreover, in
HCC, genes coding for viral proteins are often methylated (mostly
C and S) or mutated (mostly X), augmenting or even fully abrogat-
ing expression, reducing the chance of presentation of regular HBV
sequences in MHC [5,6].
In light of expressionofHBVantigensonnon-tumor liver tissue,
itwas rightly argued byQasimand colleagues that only after trans-
plantation (a minority of HCC cases), the liver is free of HBV anti-
gens, and not subject to ‘‘on-target’’ effects. After liver sparing
treatments, HBV continues to reside in the liver, rendering these
patients (the vast majority) at risk for collateral damage by HBV-
targeted therapy. Liver function in these patients is often severely
compromised by chronic HBV and thus the chance that such
therapy will destroy any remaining liver function is a high and
unacceptable risk. This, in our opinion already represents a major
obstacle, limiting widespread application. Moreover, Faria et al.
observed the recurrence ofHBV infection in 7 out of 8 patientswith
recurrent HCC after transplantation [2], indicating the high likeli-
hood of HBV antigen presence in healthy liver tissue, possibly even
higher than in tumors. Thus even in this most favourable setting
there is considerable risk of collateral damage. Although in this
case the transplanted liver was claimed to be free of HBV, the
reported high prevalence of recurrent HBV infection in recurrent
HCC [2], together with the observed rise in ALT values (indicating
treatment-induced liver damage), suggest some level of unde-
tected HBV infection may still have been present in the liver graft.
Adding this to the lack of tumor shrinkage, we have serious doubts
whether T cells attacked tumor cells rather than transplanted liver
cells and thus if therapy feasibility, as stated by the authors, was
really demonstrated.
In summary, the lack of evidence that HBV antigens are stably
expressed on HBV-related HCC cells together with the high col-
lateral damage risk, in our opinion, do not plead for targeting of
regular HBV antigens for HCC immunotherapy.
So what should be targeted? Many so called ‘‘tumor antigens’’
have been reported for (HBV-related) HCC which may represent
attractive targets (e.g., glypican 3, AFP). Similar to HBV antigens
however, these are often also expressed elsewhere in the body
and therefore also dangerous targets [7]. Recently, Bertoletti
and colleagues argued that the safest targets may be mutated
tumor proteins (e.g., neoantigens) [8]. In addition, we envision
also tumor-speciﬁc HBV antigen mutations could be safe targets,
provided stable expression. Screening for the most prevalent
mutations in host and HBV antigens, together with mapping
the tumor HLA-peptidome could lead to a panel of neoantigens
to target or to patient speciﬁc targets.
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Reply to: ‘‘To target or not to target viral antigens
in HBV related HCC?’’
To the Editor:
We welcome a discussion about the therapeutic potential of
HBV-speciﬁc TCR redirected (HBV-TCR) T cells in HBV-related
HCC offered by Buschow et al., who express strong reservations
about the conclusions of our recent work [1] and about the use
of HBV antigen as a target of HCC immunotherapy.
First, Buschow et al. challenged our idea that HBV antigen can
be used as a target for HCC immunotherapy, suggesting that in our
HBV-TCR T cell treated patient we ‘‘lack evidence to conclude that
T cells really acted on tumor cells’’. They are instead proposing
that the drop of HBsAg observed in the patient could be explained
by the T cells targeting ‘‘some level of undetectable HBV infection
of the transplanted liver’’ and not the HCC metastases.
In the liver-transplanted patient with extrahepatic HCC
metastases described in our report (see Supplementary Material
of our paper for the detailed clinical history) [1], liver biopsies
were obtained from the transplanted liver and from the extrahep-
atic HCC metastases. HBsAg was found only in HCC metastases
and not in the liver.
Furthermore, despite not being on anti-viral therapy, the
patient sera was HBsAg positive but consistently HBV-DNA
negative (a test performed monthly for the ﬁrst 3 years after
transplantation and every 3 months thereafter). HBV-DNA was
also not found in the biopsy of the transplanted liver, while a trun-
cated HBV-DNA coding only for HBsAg was detected in the biopsy
material of the HCC metastasis. We sequenced this integrated
section of HBV-DNA and demonstrated that it was coding for a
non-mutated sequence of the HBs183-91 region that is recog-
nized by our HBs183-91-directed TCR. We further characterized
the extrahepatic HCC metastasis by staining them with a T cell
receptor-like antibody speciﬁc for HBs183-91/HLA-A2 [2],
demonstrating that HCC cells of this patient presented these
speciﬁc HBV-peptide/HLA-class I complexes on their surface.
Thus, we have provided extensive experimental evidence showing
that HCC metastasis can process and present HBsAg in a form
recognizable by our adoptively transferred HBV-TCR T cells. In
contrast we failed to ﬁnd any evidence of the presence of HBV
and/or HBsAg expression in the transplanted liver of this patient.
Based on these results we have difﬁculty understanding how
Buschow could hypothesize that the HBsAg drop and the HBV-
TCR T cell expansion observed after adoptive transfer derived
from T cell recognition of HBV-infected hepatocytes (that we can-
not detect) and not, simply, from the recognition of extrahepatic
HBsAg-expressing HCC cells.
Buschow et al. may say that only ‘‘seeing is believing’’ and we
have to admit that we do not have a direct in vivo visualization of
adoptively transferred T cells interacting with HCC cells in the
patient. Nevertheless, we prefer to base our interpretation on
the experimental evidences and not on speculation.
Buschow et al. then criticized the use of HBV antigen as anHCC-
tumor antigen for immune intervention, providing arguments of
limited quantitative and temporal HBV antigen expression in
HCC cells and stressing the supposed ‘‘rarity’’ of our reported case.
They argued that ‘‘For a long lasting therapeutic effect, HBV
antigens need to be stably expressed by tumor cells and presented
by MHC-I molecules’’ and point out that we did not test in our
report if the tumor evolved to an HBsAg negative status under
immune attack. To support the limited HBV antigen expression
in HCC they quote a study of Faria et al. [3] that reported a reduced
expression ofHBsAg in tumorsdespite thepresence ofHBV-DNA in
most HCC recurrences.
The question of stability of HBsAg expression under
immunotherapy is puzzling and, we have argued in our
report that, HBV-TCR T cells could not only lyse but also
modulate HBsAg expression. Nevertheless, in previous
experiments in animal models, adoptive transfer of HBV-
TCR T cells did not suppress HBsAg production but resulted
in lysis of HCC cells [4,5].
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